Alterome Therapeutics is a targeted therapy developer focused on developing biopharmaceuticals for the treatment of cancer-specific targeted therapies that address oncogenic drivers. Alterome Therapeutics announced the completion of over $35 million in Series A financing, co-led by Colt Ventures and OrbiMed, with participation from Nextech Invest, Vida Ventures and Boxer Capital.
This article is reproduced from: https://www.itjuzi.com/investevent/13644979
This site is for inclusion only, and the copyright belongs to the original author.